IPHAのROE（自己資本利益率）は？

INNATE PHARMAのROEは466.96%です。

IPHAの配当利回りは？

INNATE PHARMAの配当利回りは0.00%です。

IPHAの品質スコア（Quality Score）は？

当社のAIはIPHAの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

IPHAは今が買い時ですか？

当社AIのタイミングスコアは100点中3点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

IPHAはどのセクターに属しますか？

INNATE PHARMAはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

IPHA (NASDAQ) 株価分析 | INNATE PHARMA

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

IPHA AI Analysis Summary

Our AI summary for IPHA: INNATE PHARMA (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 466.96%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

IPHA

INNATE PHARMA

US:NASDAQ STOCK Healthcare >> Biotechnology News 84

USD 1.75

0.01 (0.29%) Day Change

Watchlist Portfolio Compare Chart

-0.41

D/E

467.0%

ROE

-161.6%

ROA

0.00%

Div Yield

INNATE PHARMA
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.75 Price 0.01 (0.29%) Day Change	NEWS SCORE: 84

IPHA, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROAが低い
平均ROEが低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	84
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.75
PBV / Sector	-7.55 / 5.20
Earning Per Share	-1.08

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.01 M GREAT
Average 1W Daily Value	0.01 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-10,232.82 / 98.71
NPM Average (%) / Sector	-2,500.93 / -1,721.76
NPM Change Average (%) / Sector	833.00 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-161.59 / 27.02
ROA Average (%) / Sector	-63.37 / -368.17
ROA Change Average (%) / Sector	257.11 / 5,404.12 GREAT
ROE (%) / Sector	466.96 / 3.47 GREAT
ROE Average (%) / Sector	2.35 / 6.51
ROE Change Average (%) / Sector	904.65 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 08:00:01
Symbol	IPHA
Name	INNATE PHARMA
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	93.90 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	163.86 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 117, Avenue de Luminy, Marseille, France, 13009

Phone: 33 4 30 30 30 30

Website: https://www.innate-pharma.com

Employees: 164

Sector: Healthcare >> Biotechnology

Description: Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.